To unveil dregamine 5‐bromo‐pyridin‐2‐ylhydrazone (BBIT20), antitumor activity and underlying molecular mechanism of action, 2D and 3D cell cultures, patient-derived cell lines and xenograft mouse models were used.
[British Journal of Pharmacology]
6807162 {6807162:WPU7TQLX} apa 50 1 161690 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-646d731ad5b12c6efcd898b28c4cdf6d%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22WPU7TQLX%22%2C%22library%22%3A%7B%22id%22%3A6807162%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Raimundo%20et%20al.%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERaimundo%2C%20L.%2C%20Paterna%2C%20%26%23xC2%3B.%2C%20Calheiros%2C%20J.%2C%20Ribeiro%2C%20J.%2C%20Cardoso%2C%20D.%2C%20Piga%2C%20I.%2C%20Neto%2C%20S.%20J.%2C%20Hegan%2C%20D.%2C%20Glazer%2C%20P.%20M.%2C%20Indraccolo%2C%20S.%2C%20Mulhovo%2C%20S.%2C%20Costa%2C%20J.%20L.%2C%20Ferreira%2C%20M.-J.%20U.%2C%20%26amp%3B%20Saraiva%2C%20L.%20%28n.d.%29.%20BBIT20%20inhibits%20homologous%20DNA%20repair%20with%20disruption%20of%20the%20BRCA1-BARD1%20interaction%20in%20breast%20and%20ovarian%20cancer.%20%3Ci%3EBritish%20Journal%20of%20Pharmacology%3C%5C%2Fi%3E%2C%20%3Ci%3En%5C%2Fa%3C%5C%2Fi%3E%28n%5C%2Fa%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2Fhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbph.15506%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2Fhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbph.15506%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6807162%26amp%3Bitem_key%3DWPU7TQLX%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22BBIT20%20inhibits%20homologous%20DNA%20repair%20with%20disruption%20of%20the%20BRCA1-BARD1%20interaction%20in%20breast%20and%20ovarian%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liliana%22%2C%22lastName%22%3A%22Raimundo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c2ngela%22%2C%22lastName%22%3A%22Paterna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliana%22%2C%22lastName%22%3A%22Calheiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joana%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilaria%22%2C%22lastName%22%3A%22Piga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susana%20Junqueira%22%2C%22lastName%22%3A%22Neto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denise%22%2C%22lastName%22%3A%22Hegan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M.%22%2C%22lastName%22%3A%22Glazer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefano%22%2C%22lastName%22%3A%22Indraccolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silva%22%2C%22lastName%22%3A%22Mulhovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Lu%5Cu00eds%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria-Jos%5Cu00e9%20U.%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%5Cu00edlia%22%2C%22lastName%22%3A%22Saraiva%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Purpose%20Advances%20in%20the%20treatment%20of%20triple-negative%20breast%20cancer%20%28TNBC%29%20and%20ovarian%20cancer%20%28OC%29%20remain%20challenging.%20In%20particular%2C%20resistance%20to%20the%20available%20therapy%2C%20by%20restoring%20or%20overexpressing%20the%20DNA%20repair%20machinery%2C%20has%20often%20been%20reported.%20New%20strategies%20to%20improve%20the%20therapeutic%20outcomes%20of%20these%20cancers%20are%20needed.%20Herein%2C%20we%20disclose%20the%20dregamine%205-bromo-pyridin-2-ylhydrazone%20%28BBIT20%29%2C%20a%20natural%20monoterpene%20indole%20alkaloid%20derivative%2C%20as%20an%20inhibitor%20of%20homologous%20DNA%20repair%20%28HDR%29.%20Experimental%20Approach%20To%20unveil%20BBIT20%20antitumor%20activity%20and%20underlying%20molecular%20mechanism%20of%20action%2C%20two-dimensional%20%282D%29%20and%20three-dimensional%20%283D%29%20cell%20cultures%2C%20patient-derived%20cell%20lines%20and%20xenograft%20mouse%20models%20were%20used.%20Key%20results%20BBIT20%20disrupted%20the%20BRCA1-BARD1%20interaction%2C%20triggering%20nuclear-to-cytoplasmic%20BRCA1%20translocation%2C%20cell%20cycle%20arrest%20and%20downregulation%20of%20HDR-related%20genes%20and%20proteins%2C%20with%20subsequent%20enhancement%20of%20DNA%20damage%2C%20reactive%20oxygen%20species%20generation%20and%20apoptosis%2C%20in%20TNBC%20and%20OC%20cells.%20BBIT20%20also%20displayed%20pronounced%20antitumor%20activity%20in%20patient-derived%20cells%20and%20xenograft%20mouse%20models%20of%20OC%2C%20with%20low%20toxicity%20in%20non-malignant%20cells%20and%20undetectable%20side%20effects%20in%20mice.%20Additionally%2C%20it%20did%20not%20induce%20resistance%20in%20TNBC%20and%20OC%20and%20displayed%20marked%20synergistic%20effects%20with%20cisplatin%20and%20olaparib%20%28a%20poly%20%28ADP-ribose%29%20polymerase%20inhibitor%29%2C%20on%202D%20and%203D%20models%20of%20these%20cancer%20cells.%20Conclusion%20and%20Implications%20These%20findings%20add%20an%20inhibitor%20of%20the%20BRCA1-BARD1%20interaction%20to%20the%20list%20of%20DNA-damaging%20agents.%20Importantly%2C%20either%20as%20a%20single%20agent%20or%20in%20combination%20therapy%2C%20BBIT20%20reveals%20great%20potential%20in%20the%20personalized%20treatment%20of%20aggressive%20and%20resistant%20cancers%2C%20particularly%20TNBC%20and%20advanced%20OC.%22%2C%22date%22%3A%22%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbph.15506%22%2C%22ISSN%22%3A%221476-5381%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbpspubs.onlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fbph.15506%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-28T22%3A54%3A58Z%22%7D%7D%5D%7D
Raimundo, L., Paterna, Â., Calheiros, J., Ribeiro, J., Cardoso, D., Piga, I., Neto, S. J., Hegan, D., Glazer, P. M., Indraccolo, S., Mulhovo, S., Costa, J. L., Ferreira, M.-J. U., & Saraiva, L. (n.d.). BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer. British Journal of Pharmacology, n/a(n/a). https://doi.org/https://doi.org/10.1111/bph.15506 Cite